The development of new treatments for kidney disease is essential for improving patient outcomes and slowing disease progression, ultimately preventing kidney failure. In a recent interview with Good Morning Texas, nephrologist Dr. Roberto Collazo from Dallas Nephrology Associates shed light on the current treatment options available for patients with chronic kidney disease (CKD). Traditionally, treatment focused on lifestyle modifications and controlling associated conditions such as diabetes and hypertension. However, innovations in medicine have introduced promising new classes of medications.
Dr. Collazo highlighted the groundbreaking SGLT2 inhibitors, which significantly slow CKD progression in patients with diabetes, as well as non-steroidal mineralocorticoid receptor antagonists and GLP-1 agonists that also benefit conditions like obesity. The implications of these treatments are profound, especially considering recent research that suggests a strong connection between kidney health and cardiovascular conditions. This correlation is recognised as a new syndrome called cardiovascular kidney syndrome, underscoring the need for an integrated approach to treatment that addresses both kidney and heart health.
Looking ahead, there is optimism surrounding the future of kidney disease treatment, with advancements in therapies for patients suffering from immune disorders, end-stage kidney disease, and the promotion of home dialysis options. Furthermore, the field is exploring innovative possibilities such as xenotransplantation and the potential for lab-grown kidneys. For those eager to stay informed, Dr. Collazo encourages patients to regularly consult their primary care providers to discuss their kidney function and any necessary referrals to nephrologists. For more information about the latest treatment therapies, resources, and support, patients can check out the Dallas Nephrology Associates podcast, “Let’s Talk About Kidneys.”